News Summary: Merck settles cholesterol drug suits

News Summary: Drugmaker Merck to pay $688 M to settle 2 investor suits over cholesterol drugs

Associated Press

SUIT SETTLEMENT: Drugmaker Merck agreed to pay $688 million to settle two investor lawsuits over a long delay in releasing results of a study meant to show its blockbuster cholesterol drugs reduced plaque buildup in arteries. But it found that Merck's Zetia and Vytorin were no better than a cheap generic pill.

MERCK RESPONSE: Merck admits no wrongdoing and said it was in its best interest to end the suits.

FINANCIAL IMPACT: Merck took a $493 million charge and restated its 2012 financial results, reducing earnings per share by 16 cents each for the fourth quarter and the full year.

Sorry you didn't like this comment. Please provide a reason below.

Are you sure?
Rating failed. Try again.
Request failed. Try again.
We will promote constructive and witty comments to the top, so everyone sees them!
Sorry, we can’t load comments right now. Try again.

    Recommended for You